AstraZeneca/Actavis Antibiotic Review Shows Limits Of Flexibility
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee makes clear streamlined antibiotic development can only go so far despite high unmet need, giving thumbs up to two proposed indications for combination gram-negative antibiotic but nixing indication that lacks clinical trial data.